Abstract:There is a strong association between obesity, insulin resistance and type 2 diabetes mellitus. Abdominal obesity appears to be a major mediator of insulin resistance and hyperinsulinemia. Insulin resistance is a pathological condition in which cells fail to respond normally to the hormone insulin. leading to high blood sugar (impaired glucose uptake in peripheral tissues, particularly in skeletal muscle.) The more life-threatening problems fall into four main areas: type 2 diabetes, cardiovascular diseases (CVD), dyslipidemia and certain types of cancers and musculoskeletal disorders. There is considerable evidence that inflammation is a primary mediator of obesity induced insulin resistance and related co-morbidities, including diabetes and CVD whereby pro-inflammatory substances and other chemokines produced by adipocytes and macrophages are able to cause insulin resistance. The major inflammatory factors include pro-inflammatory interleukins (IL-1 & IL-6) and signaling intermediate-nuclear factor kappa B cells (NF-kB), chemokines and cytokines, tumor necrosis factor alpha (TNF-α), adiponectin (ADN), circulating C-reactive protein (CRP) concentrations, toll-like receptors (Tlr), free fatty acids (FFA), oxidative stress and dietary fatty acids. Considering this viewpoint, in the present review, we have selected ten well designed clinical studies with salsalates, thiazolidinediones (TZD) and TNF-α–antagonists to discuss and analyze these emerging therapeutic approaches for the treatment of obesity induced insulin resistance and type 2 diabetes mellitus. These therapeutics provide sufficient evidence of improved glycemic control post treatment in obese patients by targeting the state of chronic inflammation that characterizes obesity and resulted in improved insulin sensitivity by reducing adipocyte pro-inflammatory cytokine expression, adipose tissue macrophage content and immune cell infiltration into adipose tissue and other inflammatory markers. Even with looking at only few studies, analyzing each pathway, the hypothesis that targeting pro-inflammatory pathways in adipocytes with TZD and salicylates as a novel approach remains supported for reducing chronic inflammation-induced insulin resistance in obese patients, with TZD emerging with the strongest effects.

Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity

Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low‐grade inflammation and the development of obesity and diabetes

Metabolic and Molecular Mechanisms of Macrophage Polarisation and Adipose Tissue Insulin Resistance

The bioenergetics of inflammation: insights into obesity and type 2 diabetes

The role of adipose tissue immune cells in obesity and low-grade inflammation.

Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)

Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences

Epigenetic Reprogramming of the Inflammatory Response in Obesity and Type 2 Diabetes

Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity

Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes

Adipose Tissue-Resident Immune Cells in Obesity and Type 2 Diabetes

Inflammation During Obesity Is Not All Bad: Evidence From Animal And Human Studies

Adipocyte, Immune Cells, and miRNA Crosstalk: A Novel Regulator of Metabolic Dysfunction and Obesity

Review: Obesity Induced Insulin Resistance, Type 2 Diabetes and Emerging Therapeutic Approaches.

An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis

Innate lymphoid cells type 2 - emerging immune regulators of obesity and atherosclerosis

Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation

The inflammation highway: metabolism accelerates inflammatory traffic in obesity

Genetic predispositions to low-grade inflammation and type 2 diabetes